In a recent work scientists pointed out the effective regulation of the chaperone protein Hsp27.

"Our study shows that Hsp 27 may be a double-edged sword depending upon the contextual environment of neurons in the brain," said the study's principal investigator Chad Dickey.
"By better defining the mechanisms linking chaperone proteins to both the tau aggregation and degradation pathways, we can move toward more individualized, effective therapies targeting Alzheimer's and other distinct neurological disorders," said Dickey.
The USF study was done using mice genetically engineered to develop tau protein tangles like those found in the brains of people with Alzheimer's disease.
In one experiment, the researchers injected into the brains of 4-month-old Alzheimer's mice viral particles expressing either dynamic wild-type Hsp27 or genetically altered Hsp27 that was continuously on or activated.
By four months, the Alzheimer's mice have aged enough to have large amounts of tau accumulated but are still able to clear the protein before insoluble toxic tangles take over.
Advertisement
In another experiment, the researchers examined the physiological effects of Hsp27 overexpression in the brain.
Advertisement
The researchers concluded that Hsp27 must be able to fluctuate between activated and de-activated states to succeed at clearing abnormal tau, thus preventing the protein from sticking together and building up excessively in the brain.
In addition, Hsp27 can only be effective in helping maintain healthy tau turnover if the chaperone protein interacts with tau while it's still soluble-before tau has developed into solid nerve-killing tangles. The chaperone protein cannot disrupt already formed tau tangles.
The findings were published in the Journal of Neuroscience.
Source-ANI